The second study presented at the SITC meeting focuses on a “next-generation” approach following TIL therapy, utilizing ...

Available funding totaling EUR 20 million dedicated to developing novel solid tumor treatments addressing a high unmet medical need Springboard ...

Preclinical data with TK-6302 has shown best-in-class anti-tumor efficacy, demonstrating its potential to elicit deep and ...

Groundbreaking studies reveal the potential of cell therapies to achieve long-term remission in HPV-associated cancers, ...

Xiangxue Life Sciences has agreed a strategic partnership with Guangzhou-based Damien Vaccines to co-develop in vivo TCR-T ...

Captain T Cell GmbH has successfully closed an equity financing round to support its T-cell receptor (TCR) T-cell therapies for solid tumors. The company’s autologous lead program, CTC-127, is a ...

Cellular therapies, including TIL, TCR, and CAR-T, are transforming lung cancer care by utilizing personalized immune cells ...

IB [email protected] of Chicago School of Medicine achieves first-ever automated 3-in-1 TCR-T manufacturing on Terumo Blood and Cell Technologies Quantum Flex Bioreactor ...

Therapeutics, a biotech developing next-generation T cell receptor (TCR) therapeutics for cancer and autoimmune disease, has ...

Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally. Often diagnosed at advanced stages, the therapeutic ...